Abstract
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein composed of HIF-1α and HIF-1α subunits, which is activated in response to reduced O2 availability. HIF-1 transactivates genes encoding proteins that are involved in key aspects of the cancer phenotype, including cell immortalization and de-differentiation, stem cell maintenance, genetic instability, glucose uptake and metabolism, pH regulation, autocrine growth/survival, angiogenesis, invasion/metastasis, and resistance to chemotherapy. Increased HIF-1α levels, as determined by immunohistochemical analysis of tumor biopsy specimens, is associated with increased mortality in many human cancers. Drugs that inhibit HIF-1 activity and have anti-cancer effects in vivo have been identified and clinical trials are warranted to establish the contexts in which addition of such agents to therapy protocols will result in increased patient survival.
Keywords: Angiogenesis, cancer, chemotherapy, hypoxia-inducible factor, invasion, metastasis, metronomic therapy, oxygen
Current Pharmaceutical Design
Title: HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Volume: 15 Issue: 33
Author(s): G. L. Semenza
Affiliation:
Keywords: Angiogenesis, cancer, chemotherapy, hypoxia-inducible factor, invasion, metastasis, metronomic therapy, oxygen
Abstract: Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein composed of HIF-1α and HIF-1α subunits, which is activated in response to reduced O2 availability. HIF-1 transactivates genes encoding proteins that are involved in key aspects of the cancer phenotype, including cell immortalization and de-differentiation, stem cell maintenance, genetic instability, glucose uptake and metabolism, pH regulation, autocrine growth/survival, angiogenesis, invasion/metastasis, and resistance to chemotherapy. Increased HIF-1α levels, as determined by immunohistochemical analysis of tumor biopsy specimens, is associated with increased mortality in many human cancers. Drugs that inhibit HIF-1 activity and have anti-cancer effects in vivo have been identified and clinical trials are warranted to establish the contexts in which addition of such agents to therapy protocols will result in increased patient survival.
Export Options
About this article
Cite this article as:
Semenza L. G., HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery, Current Pharmaceutical Design 2009; 15 (33) . https://dx.doi.org/10.2174/138161209789649402
DOI https://dx.doi.org/10.2174/138161209789649402 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Meet Our Editorial Board Member
Current Cardiology Reviews Phytoestrogens and Prostate Cancer
Current Drug Targets New Insight into Urate-Related Mechanism of Cardiovascular Damage
Current Pharmaceutical Design Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry Validation of Acute Liver Injury Cases in a Population-Based Cohort Study of Oral Antimicrobial Users
Current Drug Safety Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature
Current Pharmaceutical Design Editorial [Hot Topic: Calcium Regulatory Proteins as Therapeutic Targets (Guest Editor: Livia C. Hool)]
Current Drug Targets Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Nutraceuticals and Dietary Supplements to Improve Quality of Life and Outcomes in Heart Failure Patients
Current Pharmaceutical Design Nanotechnology and Treatment of Cardiovascular Disease: A Review of Nanoscale Innovations for Regenerative Therapy
Current Nanomedicine The Effects of Fusion Structure on the Expression and Bioactivity of Human Brain Natriuretic Peptide (BNP) Albumin Fusion Proteins
Current Pharmaceutical Biotechnology Influence of Ultrasound Mediated Transdermal Delivery of Losartan Potassium
Drug Delivery Letters Novel Strategies to Delineate Matrix Metalloproteinase (MMP)-Substrate Relationships and Identify Targets to Block MMP Activity
Mini-Reviews in Medicinal Chemistry Initiation of Dialysis: A Mini-Review of a Changing Paradigm
Cardiovascular & Hematological Disorders-Drug Targets Clinically Relevant Extracellular-Matrix Scaffolds for Cell Transplantation and Vascular Repair
Current Vascular Pharmacology Effects of Myricitrin and Relevant Molecular Mechanisms
Current Stem Cell Research & Therapy Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges
Cardiovascular & Hematological Agents in Medicinal Chemistry The Pathogenesis of Susceptibility to Acute Kidney Injury in the Elderly
Current Aging Science The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design